Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE7A | Q13946 | 1/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27119230 | 0.88 | PDE7A (0.36) | PDE7APDE3APDE10ACA12CA2 | |
| SCHEMBL12046678 | 0.87 | PDE10A (0.45) | PDE7APDE3APDE10ACA12CA2 | |
| SCHEMBL27119151 | 0.86 | CA12 (0.39) | CA12CA2CA9 | |
| SCHEMBL27118935 | 0.86 | PDE7A (0.38) | PDE7APDE3APDE10ACA12CA2 | |
| SCHEMBL29539301 | 0.86 | PDE7A (0.32) | PDE7APDE3APDE10A | |
| SCHEMBL16334006 | 0.86 | PDE7A (0.32) | PDE7APDE3APDE10A | |
| SCHEMBL30759543 | 0.84 | PDE7A (0.35) | PDE7APDE3APDE10ACA12CA2 | |
| SCHEMBL27119255 | 0.84 | PDE7A (0.35) | PDE7APDE3APDE10ACA12CA2 | |
| SCHEMBL30759604 | 0.84 | PDE7A (0.35) | PDE7APDE3APDE10ACA12CA2 | |
| SCHEMBL27119238 | 0.84 | PDE7A (0.35) | PDE7APDE3APDE10ACA12CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260008783-A1 | MODULATORS OF FSHR AND USES THEREOF | GEDEON RICHTER PLC (HU) | 2026-01-08 | — | — | US | disclosed |
| EP-4577206-A2 | NOVEL MODULATORS OF FSHR AND USES THEREOF | Celmatix Inc. (US) | 2025-07-02 | — | — | EP | disclosed |
| WO-2024044778-A2 | NOVEL MODULATORS OF FSHR AND USES THEREOF | CELMATIX INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| WO-2024044778-A2 | NOVEL MODULATORS OF FSHR AND USES THEREOF | CELMATIX INC. (US) | 2024-02-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260008783-A1 | MODULATORS OF FSHR AND USES THEREOF | FSHR, GNRHR, LHCGR | PDE7A 400/4885PDE3A 386/4885PDE10A 741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.